

## Neurological evaluation - anywhere, anytime

Ziv Yekutieli

### ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Please complete the ABSTRACT TEMPLATE online, for Biomed 2026 Company Presentations

All items marked with an \* are mandatory to complete

The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name: Mon4t \* Website: [www.mon4t.com](http://www.mon4t.com)

CEO name: Ziv Yekutieli Cell phone number 053-5826262 Email: [ziv@mon4t.com](mailto:ziv@mon4t.com)

Select a CATEGORY: Medical Devices

Select one SESSION per abstract from the list below \*

“AI as an Equalizer: From Center to Periphery in Healthcare.”

Answers below should not exceed 60 words per question:

- **Executive Summary:**
  - Mon4t delivers FDA-cleared smartphone-based neurological assessment. It targets clinical trials, remote monitoring, and aging populations. The company combines neuroscience and engineering expertise, positioning itself as a scalable digital biomarker platform for CNS research and care.
- **Core Technology:**
  - Mon4t uses smartphone sensors to derive digital biomarkers. It uniquely provides high temporal resolution, multimodal data fusion, and no-hardware deployment. The platform transforms subjective assessments into objective, sensitive, and scalable measurements aligned with clinical endpoints.
- **Product Profile/Pipeline:**
  - The platform includes motor, cognitive, and behavioral assessments deployed via smartphone. It is FDA-cleared and used in clinical trials. Applications span CNS drug development and remote monitoring. Ongoing work expands condition-specific biomarkers and partnerships with pharma and digital health platforms.
- **Business Strategy**
  - Mon4t operates B2B, serving pharma, CROs, and healthcare providers. Revenues come from clinical trial deployments and SaaS licensing. Long-term strategy focuses on integration into standard care and digital health ecosystems, becoming the core measurement layer for neurological and cognitive function.
- **What's Next?**
  - Focus areas include expanding biomarker capabilities, advancing AI analytics, and securing additional regulatory clearances. Plans include scaling partnerships, increasing clinical validation, and growing commercial operations. Financial strategy emphasizes commercialization and strategic collaborations to support adoption and long-term growth.

